POTP Point Therapeutics (MM)

Point Therapeutics, Inc. (NASDAQ: POTP) announced today that it will release third quarter 2006 results on Thursday, November 9, 2006, after the close of the U.S. financial markets. A conference call will follow at 4:30 PM Eastern Time, to review the results and provide an update on the Company's progress. Participants are invited to attend the call by visiting www.pther.com or by dialing: 800-591-6944 (International: 617-614-4910) Passcode: 66385651 A re-broadcast of the conference call will be available until November 16, 2006 and accessible by dialing: 888-286-8010 (International: 617-801-6888) Passcode: 78019990 About Point Therapeutics, Inc.: Point is a Boston-based biopharmaceutical company developing a portfolio of dipeptidyl peptidase (DPP) inhibitors for use in cancer, type 2 diabetes and as vaccine adjuvants. Point is currently studying its lead product candidate, talabostat, in two Phase 3 trials in non-small cell lung cancer. Point is also studying talabostat in several Phase 2 trials, including as a single-agent in metastatic melanoma, in combination with cisplatin in metastatic melanoma, in combination with rituximab in advanced chronic lymphocytic leukemia, and in combination with gemcitabine in metastatic pancreatic cancer. Point Therapeutics, Inc. (NASDAQ: POTP) announced today that it will release third quarter 2006 results on Thursday, November 9, 2006, after the close of the U.S. financial markets. A conference call will follow at 4:30 PM Eastern Time, to review the results and provide an update on the Company's progress. Participants are invited to attend the call by visiting www.pther.com or by dialing: 800-591-6944 (International: 617-614-4910) Passcode: 66385651 A re-broadcast of the conference call will be available until November 16, 2006 and accessible by dialing: 888-286-8010 (International: 617-801-6888) Passcode: 78019990 About Point Therapeutics, Inc.: Point is a Boston-based biopharmaceutical company developing a portfolio of dipeptidyl peptidase (DPP) inhibitors for use in cancer, type 2 diabetes and as vaccine adjuvants. Point is currently studying its lead product candidate, talabostat, in two Phase 3 trials in non-small cell lung cancer. Point is also studying talabostat in several Phase 2 trials, including as a single-agent in metastatic melanoma, in combination with cisplatin in metastatic melanoma, in combination with rituximab in advanced chronic lymphocytic leukemia, and in combination with gemcitabine in metastatic pancreatic cancer.